Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma

Severe ascites is an adverse event of ramucirumab (RAM), a second-line treatment for hepatocellular carcinoma (HCC). Ascites can be associated with various factors, including nutritional status and muscle quality. The aim of the present study was to investigate the prevalence and profiles of RAM-ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamachi, Naoki, Shimose, Shigeo, Hirota, Keisuke, Koya, Shunji, Iwamoto, Hideki, Niizeki, Takashi, Shirono, Tomotake, Nakano, Masahito, Hashida, Ryuki, Kawaguchi, Takumi, Matuse, Hiroo, Noguchi, Kazunori, Koga, Hironori, Torimura, Takuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947949/
https://www.ncbi.nlm.nih.gov/pubmed/33758660
http://dx.doi.org/10.3892/mco.2021.2241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947949/
https://www.ncbi.nlm.nih.gov/pubmed/33758660
http://dx.doi.org/10.3892/mco.2021.2241

Ejemplares similares